Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


The Market for Breast Cancer Therapies in the BRIC Countries Will Grow at an Annual Rate of Eight Percent From $1.7 Billion to $2.5 Billion Between 2012 and 2017
The Launch of New Agents, an Increased Use of Targeted Therapies and a Rising Incident Population Will Contribute to BRIC Market Growth for the Treatment of Breast Cancer

BURLINGTON, Mass., Feb. 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow eight percent annually over the next five years, from $1.7 billion to $2.5 billion. The market's growth can be attributed to the launch of several premium priced agents, a gradual increase in the use of targeted therapies and a rise in the incident population.

According to the Emerging Markets report entitled Breast Cancer in the BRIC Markets, the Brazilian breast cancer market is currently the largest of the BRIC and accounts for 50 percent of the total market share for breast cancer therapies. However, while these market shares will remain consistent, the Chinese market is anticipated to develop the most through 2017.

"Among the BRIC nations, China will experience the greatest growth over the forecast period," said Decision Resources Analyst Andreia Ribeiro, Ph.D. "This will primarily be driven by the rising number of incident cases and changes in medical practice towards more personalized treatments, especially trastuzumab and GlaxoSmithKline's soon-to-launch Tykerb."

The report findings reveal that HER2-targeting agent trastuzumab (Roche's Herceptin) is the brand leader in sales across all the BRIC markets in 2012, and in 2017, it maintains its premium position despite loss of market share. Overall, the use of targeted therapies is expected to increase in the BRIC, garnering sales of $615 million to $1.16 billion between 2012 and 2017. Increased and improved patient access to these costlier agents – aided by the entry of a biosimilar version of trastuzumab – will be major drivers of sales in these markets.

Growth of the breast cancer markets in the BRIC will also be determined by the launch of several new therapies over the forecast period, which will be comprised of novel and modified HER2-targeting agents (Roche's Perjeta and Roche's antibody-drug conjugate, trastuzumab-DM1), novel chemotherapeutic agents (Eisai's Halaven and Bristol-Myers Squibb's Ixempra) and a novel targeted therapy (Novartis's Afinitor). Together, these emerging therapies will contribute approximately nine percent to overall breast cancer sales in the BRIC markets in 2017.

The new report features extensive primary research with BRIC oncologists as well as a market outlook for key drugs through 2017 and breast cancer epidemiology through 2021.

About Emerging Markets Reports
Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:



Decision Resources

Decision Resources Group

Allison Thrower

Liz Marshall

781-993-2604

781-993-2563

athrower@dresourcesgroup.com

emarshall@dresourcesgroup.com

SOURCE Decision Resources

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
We often get asked “Should I use GridFS for file storage with MongoDB”. As with most things, the answer is a staunch “it depends”. GridFS looks like a great idea on paper - a virtual filesystem held within MongoDB which allows for larger than 16MB files to be held, synced and replicat...
The supply chain is evolving, and buyers need to analyze and predict, but also to manage risk. When Capgemini's business information management (BIM) practices unit needed to provide big data capabilities to its insurance company customers, it needed to deliver the right information t...
Some people believe good or bad things always happen in threes. I believe you will always be able to find three (and probably more) things that are good or bad and somewhat related, but sometimes I get surprised by the apparent coincidental appearance of several closely related “things...
This article defines long polling and presents a few techniques on how long polling could be used in Spring MVC web applications. Discussion covers both the AJAX and the server part of the solution as well as outlines a few possible options for implementation. The article compares perf...
Red Hat, Inc., on Wednesday announced that it has signed a definitive agreement to acquire eNovance, a provider of open source cloud computing services. Combined with Red Hat’s existing leadership in OpenStack, the addition of eNovance’s systems integration capabilities and engineering...
Hear from Red Hat leaders and industry experts on Tuesday, June 10, 2014, at 11am and see how Red Hat Enterprise Linux continues to deliver unmatched customer value, increased efficiency, and true strategic advantage for global customers across every industry. Attendees will learn mor...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE